Saturday, October 31, 2026

Duke Energy's $103B AI Power Bet Reflects a Global Utility Reckoning

Duke Energy has committed $103B in capital expenditure over five years, driven by electricity contracts with AI hyperscalers — a pattern now reshaping utility investment from the US Carolinas to Europe and Asia. The plan includes next-generation nuclear, signaling long-duration demand. Duke's CEO says the figure will grow.

LM Salvado
LM Salvado

April 27, 2026

Duke Energy's $103B AI Power Bet Reflects a Global Utility Reckoning
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Duke Energy has committed billions in capital expenditure over five years, anchored by electricity supply agreements with hyperscalers expanding AI data center capacity.1 The plan includes next-generation nuclear. Duke's CEO has signaled the total will rise.

The dynamic is not uniquely American. Utilities in the UK, Germany, Japan, and South Korea are under equivalent pressure as hyperscalers accelerate global AI buildouts. In the Middle East, Saudi Arabia and the UAE are constructing dedicated power infrastructure for AI campuses before demand fully materializes. China's state-owned utilities are absorbing AI data center load directly into national grid planning.

The scale of AI power demand explains why. A conventional enterprise data center draws 5–10 megawatts. AI training clusters routinely require 100MW or more per site.1 Dozens of facilities under simultaneous construction push aggregate demand into gigawatts — utility-scale, not IT-scale.

Hyperscalers need continuous, high-density power. Intermittent renewables cannot anchor AI infrastructure alone. That constraint is driving nuclear back into utility planning globally. France has long relied on nuclear baseload. The UK, South Korea, and Canada are advancing small modular reactor programs. Duke's inclusion of next-gen nuclear in its capex plan reflects the same logic: hyperscalers are willing to contract long-term for carbon-free baseload, and utilities that can provide it capture demand before nuclear developers bypass them with direct agreements.1

Duke's service territory in the Carolinas and Midwest has become a concentration point for US AI infrastructure.1 But the investment cycle it is entering — grid upgrades, new generation, expanded transmission — is being replicated across every major economy where AI compute is concentrating.

If Duke's CEO is correct that billions is a floor, the pattern will compound. Utility capex cycles lag demand by years. The AI buildout is still accelerating.1

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com